Steigerwald Gordon & Koch Inc. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 19.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,989 shares of the company’s stock after buying an additional 823 shares during the quarter. Steigerwald Gordon & Koch Inc.’s holdings in Merck & Co., Inc. were worth $455,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. Joseph P. Lucia & Associates LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $25,000. Landmark Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $25,000. Front Row Advisors LLC lifted its stake in shares of Merck & Co., Inc. by 89.4% in the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after purchasing an additional 160 shares during the period. Okabena Investment Services Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $27,000. Finally, Western Pacific Wealth Management LP acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $29,000. 73.33% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Stock Performance
MRK stock opened at $87.51 on Friday. Merck & Co., Inc. has a 12-month low of $71.50 and a 12-month high of $95.72. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average of $88.83 and a 200-day moving average of $87.81. The firm has a market cap of $221.69 billion, a PE ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33.
Merck & Co., Inc. Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a $0.69 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.76 annualized dividend and a yield of 3.15%. Merck & Co., Inc.’s payout ratio is 42.27%.
Analyst Ratings Changes
A number of analysts recently commented on the company. Erste Group Bank raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, August 25th. Morgan Stanley boosted their target price on Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. UBS Group boosted their target price on Merck & Co., Inc. from $76.00 to $98.00 and gave the company a “neutral” rating in a research report on Monday, July 18th. Mizuho assumed coverage on Merck & Co., Inc. in a research report on Friday, June 24th. They issued a “buy” rating and a $100.00 target price for the company. Finally, SVB Leerink boosted their target price on Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research report on Monday, September 12th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.28.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.